scholarly journals Multisensory Stimulation in Dementia

2020 ◽  
Vol 3 (1) ◽  
pp. 123-130
Author(s):  
Masoome Zaree ◽  

Background & Objectives: Dementia is a prevalent disorder around the world. However, its chronic and progressive nature mostly affects physical and psychosocial characteristics and public healthcare. Recently, multisensory interventions have been used in people with dementia as one of the nonpharmacological treatment methods. This narrative review intends to explain multisensory stimulation programs or Snoezelen for those affected with dementia. Methods: Keywords such as “sensory-based intervention”, “sensory stimulation”, “sensory processing”, “Snoezelen”, “sensory modulation”, and “dementia” were used in Scopus and PubMed databases with a sensitive search strategy in the articles published between 2000 and 2020. Results: The initial search retrieved 255 articles. After reviewing and rejecting some duplicates, 65 studies remained in the field of multisensory interventions in dementia. However, only 8 articles fulfilled the inclusion criteria. Conclusion: Multisensory stimulations in dementia can be used as an adjunctive strategy alongside other therapies. Sensory diets can be applied in common home environments. For this purpose, it is better to use Dunn’s sensory processing model. So, along with individual components, context and occupations are also considered.

2021 ◽  
Vol 7 ◽  
pp. 233372142110135
Author(s):  
Lillian Hung ◽  
Allison Hudson ◽  
Mario Gregorio ◽  
Lynn Jackson ◽  
Jim Mann ◽  
...  

Aims: This scoping review explores key strategies of creating inclusive dementia-friendly communities that support people with dementia and their informal caregiver. Background: Social exclusion is commonly reported by people with dementia. Dementia-friendly community has emerged as an idea with potential to contribute to cultivating social inclusion. Methods: This scoping review follows the Joanna Briggs Institute scoping review methodology and took place between April and September 2020. The review included a three-step search strategy: (1) identifying keywords from CINAHL and AgeLine; (2) conducting a second search using all identified keywords and index terms across selected databases (CINAHL, AgeLine, MEDLINE, PsycINFO, Web of Science, ProQuest, and Google); and (3) hand-searching the reference lists of all included articles and reports for additional studies. Results: Twenty-nine papers were included in the review. Content analysis identified strategies for creating dementia-friendly communities: (a) active involvement of people with dementia and caregivers (b) inclusive environmental design; (c) public education to reduce stigma and raise awareness; and (d) customized strategies informed by theory. Conclusion: This scoping review provides an overview of current evidence on strategies supporting dementia-friendly communities for social inclusion. Future efforts should apply implementation science theories to inform strategies for education, practice, policy and future research.


2021 ◽  
pp. 026921632110254
Author(s):  
Bria Browne ◽  
Nuriye Kupeli ◽  
Kirsten J Moore ◽  
Elizabeth L Sampson ◽  
Nathan Davies

Background: Dementia is a life-limiting condition that affects 50 million people globally. Existing definitions of end of life do not account for the uncertain trajectory of dementia. People living with dementia may live in the advanced stage for several years, or even die before they reach the advanced stage of dementia. Aim: To identify how end of life in people with dementia is measured and conceptualised, and to identify the factors that contribute towards identifying end of life in people with dementia. Design: Systematic review and narrative synthesis. Data Sources: Electronic databases MEDLINE, EMBASE, PsychInfo and CINAHL, were searched in April 2020. Eligible studies included adults with any dementia diagnosis, family carers and healthcare professionals caring for people with dementia and a definition for end of life in dementia. Results: Thirty-three studies met the inclusion criteria. Various cut-off scores from validated tools, estimated prognoses and descriptive definitions were used to define end of life. Most studies used single measure tools which focused on cognition or function. There was no pattern across care settings in how end of life was defined. Healthcare professionals and family carers had difficulty recognising when people with dementia were approaching the end of life. Conclusion: End-of-life care and research that focuses only on cognitive and functional decline may fail to recognise the complexities and unmet needs relevant to dementia and end of life. Research and clinical practice should adopt a needs-based approach for people with dementia and not define end of life by stage of disease.


2021 ◽  
Vol 02 ◽  
Author(s):  
Inshia Begum ◽  
Fathima Murthuza ◽  
Juwairiya Syed Iqbaluddin ◽  
Hafsah Fatima Arsal

Background: The pandemic caused by Coronavirus Disease 2019 (COVID-19), also known as Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2), is believed to be one of the greatest threats to global health in the 21st century. Recent collective evidence has warranted Ruxolitinib as a potential agent in recovery. Ruxolitinib is a potent and selective inhibitor of Jack kinase (JAK) 1 and 2 with modest to marked selectivity against tyrosine kinase two and JAK3. Objective: The review aims to outline the current evidence regarding the repurposed treatment for COVID- 19 and give insight into the clinical trials. There has been considerable interest in introducing existing therapeutic agents against COVID-19 to reduce the severity of illness and ease the burden on public healthcare systems. Method: A literature search was conducted using keywords like ‘Ruxolitinib trial’ and ‘COVID-19 Ruxolitinib’ on PubMed, Google Scholar, Science Direct, and Cochrane databases to select research papers and articles on the topic published from January to October 2020. Inclusion criteria were restricted to articles on Ruxolitinib and COVID. In contrast, the exclusion criteria stipulated that any study done on COVID-19 involving a mixed treatment regimen with Ruxolitinib and other drug/s or any studies not pertinent to the purpose of the study would be omitted. Conclusion: Based on the successful outcomes of various researches conducted and clinical trials performed, the use of Ruxolitinib has shown significant improvement and faster clinical recovery among COVID-19 patients of varying severity of infection, advanced age, and multiple comorbidities. This review provides an overview of various such studies with their promising outcomes.


2019 ◽  
Vol 7 (1) ◽  
pp. 58-79 ◽  
Author(s):  
Victor Counted

The purpose of this article is to analyze how the concept of African Christian diaspora religion and/or spirituality, as a missionary-based model, is currently being used and defined within African transnational research and diaspora religion. I conducted a review using a citation search strategy to retrieve peer-reviewed articles that explore the extent to which the seminal paper of Steven Vertovec on “Diaspora Religion” has informed the conceptualization and analysis of the concept of African Christian diaspora religion and/or spirituality (ACDRS). The search generated empirical articles which met the inclusion criteria and were included for concept analysis. This concept analysis identified five emerging attributes of ACDRS as (a) a network of support, (b) a transnational dynamic, (c) a platform for civic engagement and activism, (d) the basis for developing place bonds and diaspora identity, and (e) as an experiential religion. These defining attributes position ACDRS as a multidimensional concept encompassing noninstitutionalized religious expressions and activities, albeit with limited empirical data. I also discussed some study limitations and conceptual issues related to the attributes, antecedents, consequences, and cases of ACDRS.


2020 ◽  
Vol 16 (S7) ◽  
Author(s):  
Patrick Pui Kin Kor ◽  
Clare Yu ◽  
Justina Yat Wa Liu ◽  
Daphne Sze Ki Cheung ◽  
Rick Yiu Cho Kwan ◽  
...  

2012 ◽  
Vol 6 (1) ◽  
pp. 5 ◽  
Author(s):  
Paraskevi Theofilou ◽  
Helen Panagiotaki

Adherence to medication has been recognized as a key issue in health outcomes and efforts to improve patients’ adherence are being made by the pharmaceutical industry, experts, and government bodies alike. This paper presents a review of these issues according to previous descriptive findings. Relevant studies written in English, published in 1976 or later, were identified through Medline, Embase and PsycInfo databases and reviewed. Review articles and clinical trials were excluded; all observational studies and surveys were considered. Articles were reviewed for any discussion of patients’ characteristics and psychosocial characteristics affecting <em>adherence</em> to <em>cancer</em> treatment. The search strategy included a combination of key words adherence and cancer in titles. The major findings are summarized and presented under two main headings: i) patients’ characteristics; and ii) psychosocial characteristics. In general, factors associated with increased likelihood of adherence to cancer treatment included younger age, higher education, higher income and Caucasian ethnicity. With regards to the psychosocial factors, lower levels of depression and anxiety, optimism as well as social support seemed to have a positive effect on treatment adherence. Studies of patterns of care in cancer treatment can help identify challenges in health care provided to particular subgroups of cancer patients and can aid researchers in designing studies that account for such factors in clinical and outcomes’ research.


2013 ◽  
Vol 41 (3) ◽  
pp. 558-568 ◽  
Author(s):  
Nicola Dalbeth ◽  
Cathy S. Zhong ◽  
Rebecca Grainger ◽  
Dinesh Khanna ◽  
Puja P. Khanna ◽  
...  

Objective.Five core domains have been endorsed by Outcome Measures in Rheumatology (OMERACT) for acute gout: pain, joint swelling, joint tenderness, patient global assessment, and activity limitation. We evaluated instruments for these domains according to the OMERACT filter: truth, feasibility, and discrimination.Methods.A systematic search strategy for instruments used to measure the acute gout core domains was formulated. For each method, articles were assessed by 2 reviewers to summarize information according to the specific components of the OMERACT filter.Results.Seventy-seven articles and abstracts met the inclusion criteria. Pain was most frequently reported (76 studies, 20 instruments). The pain instruments used most often were 100 mm visual analog scale (VAS) and 5-point Likert scale. Both methods have high feasibility, face and content validity, and within- and between-group discrimination. Four-point Likert scales assessing index joint swelling and tenderness have been used in numerous acute gout studies; these instruments are feasible, with high face and content validity, and show within- and between-group discrimination. Five-point Patient Global Assessment of Response to Treatment (PGART) scales are feasible and valid, and show within- and between-group discrimination. Measures of activity limitations were infrequently reported, and insufficient data were available to make definite assessments of the instruments for this domain.Conclusion.Many different instruments have been used to assess the acute gout core domains. Pain VAS and 5-point Likert scales, 4-point Likert scales of index joint swelling and tenderness and 5-point PGART instruments meet the criteria for the OMERACT filter.


2014 ◽  
Vol 29 (7) ◽  
pp. 637-647 ◽  
Author(s):  
Ana Maseda ◽  
Alba Sánchez ◽  
Ma Pilar Marante ◽  
Isabel González-Abraldes ◽  
Carmen de Labra ◽  
...  

2018 ◽  
Vol 1 (21;1) ◽  
pp. 111-120 ◽  
Author(s):  
Artemios K. Artemiadis

Background: Neuropathic pain (NP) is a common symptom caused by lesions or diseases of the somatosensory nervous system. Acute/subacute peripheral neuropathies (APN) are rare, however can be particularly painful. Objectives: The aim of this systematic review was to estimate the incidence of NP in APN and overview the various etiologies of such neuropathies. Study Design: Systematic review. Setting: Medline search. Methods: We hand-searched Medline for observational studies published between 1995 and 2017. Results: Our search strategy identified 1,400 papers. Of these, 70 met our inclusion criteria and were included in this review. Out of a total of 2,341 patients, 1,139 patients were diagnosed with NP (pooled incidence of NP 48.7%). In Guillain-Barré syndrome (GBS), the commonest cause of APN, the pooled estimate of NP was 34.8%. Other causes of painful APN include immunemediated, vasculitic, metabolic, nutritional, toxic, paraneoplastic, and infectious. Limitations: An important limitation was that GBS accounted for the majority of patients with APN, as such the calculated incidence reflected mainly this disease entity. Another important limitation was that very few studies targeted primarily NP. Thus, it is highly likely that observational studies reporting NP were missed. Finally there could always be a publication bias due to underreporting and gray literature. Conclusions: NP is a cardinal manifestation of APN. The use of validated diagnostic tools and accepted diagnostic criteria of NP is recommended for both clinical and research purposes. Key words: Neuropathic, pain, acute, subacute, neuropathy, polyneuropathy, frequency, incidence


Sign in / Sign up

Export Citation Format

Share Document